Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models
© Chen et al. 2016
Received: 21 October 2015
Accepted: 26 January 2016
Published: 4 February 2016
The Erratum to this article has been published in Journal of Biomedical Science 2017 24:48
suPAR biomarker generally considered a pathogenic factor in FSGS. However, studies have been published that dispute this conclusion. The current study was designed to investigate the roles of uPA and suPAR in FSGS in clinical and mouse models.
Clinical subjects including those with biopsy-proven FSGS and MCD were enrolled. To verify the role of uPA in FSGS, Adriamycin was used to induce FSGS in uPA knockout (uPA−/−) and BALB/c (WT) mice. Proteinuria and suPAR, the cleaved/intact forms of the circulating suPAR, and possible proteases involving cleavage of the suPAR were also studied.
FSGS clinical cases presented significantly higher serum levels of suPAR and Cr and lower serum levels of uPA. In the mice model, the uPA−/− group exhibited faster disease progression and worsening proteinuria than the WT group. In addition, the uPA−/− group had higher plasma suPAR levels, glomerular cell apoptosis, and dysregulation of the Th1/Th2 balance. In an analysis of suPAR variants in FSGS, both the intact and cleaved forms of the suPAR were higher in clinical subjects and the mouse model. However, the process of suPAR cleavage was not mediated by enzymatic activities of the uPA, elastase, or cathepsin G.
A deficiency of uPA accelerated the progression of Adriamycin-induced mouse FSGS model. Decrease of serum uPA levels may be an indicator of the progression of FSGS in clinical subjects and animal models.
KeywordsFocal and segmental glomerulosclerosis Soluble urokinase-type plasminogen activator receptor Urokinase-type plasminogen activator Th1/Th2 balance
Focal and segmental glomerulosclerosis (FSGS) accounts for up to 20 % of glomerular disease and is a major cause of end-stage renal disease (ESRD). The pathogenesis of FSGS and underlying causes remain unclear; however, it was postulated that certain circulating factors may be responsible for initiating renal injury . In 2011, Wei et al. identified increased levels of the soluble urokinase-type plasminogen activator (uPA) receptor (suPAR) in approximately two-thirds of patients with FSGS, and suPAR levels were predictive of FSGS recurrence in transplanted kidneys . They suggested that serum suPAR may be a circulating factor causing FSGS . In contrast, a cohort study by Meijers et al. did not support use of the suPAR as a biomarker for FSGS , and suggested that the currently available measurement by suPAR assays had no proven clinical value in patients with FSGS . The role of the suPAR in the progression of FSGS remains controversial.
The suPAR is derived from the uPAR, which is expressed on the cell surface of multiple cell types, including vascular endothelial cells and immune cells. Cell-surface plasminogen activation is catalyzed by the binding of the uPA and uPAR, which facilitates the binding of plasminogen to the cell surface, and controls fibrinolysis [6, 7]. In addition, the uPAR is also involved in many other non-proteolytic biological processes, such as cell migration, adhesion, angiogenesis, and cell proliferation [8–10]. The primary structure of the mature uPAR is formed by approximately 90-amino-acid, cysteine-rich LY6-like, short linker regions connecting three homologous domains (D1, D2, and D3, numbered from the N-terminus) that are linked to cell membranes by glycosylphosphatidylinositol (GPI) [11, 12]. The uPAR binds the uPA in a pocket comprising three extracellular domains, while the entire external surface interacts with other signaling molecules such as integrins, formyl peptide receptors, and epithelial growth factor receptor, the mannose-6-phosphate receptor, the family of low-density lipoproteins receptor-related proteins, p130, and others [13–15]. The GPI-anchored membranous uPAR can be cleaved to various soluble forms of the uPAR (suPAR), including glycolipid-anchored and soluble forms of the intact uPAR D1 ~ D3, and the cleaved receptor, uPAR (D2 ~ D3) and uPAR (D1) [16, 17]. It was suggested that the proteolytic cleavage of the uPAR between D1 and D2 depends on the binding of the uPA and plasmin . suPAR levels in human body fluids are quite stable in healthy individuals, while increased levels can be observed in the plasma and serum with several disease conditions, such as immunological disorders and cancers [19–21]. Both intact and cleaved suPAR variants may have diagnostic and prognostic values in cancer, inflammation, and metabolic diseases; in addition, cleaved forms of the suPAR were suggested to be stronger prognostic markers for cancer diagnoses . To the present, the composition of different circulating suPAR variants in FSGS patients has not been studied.
In general, it is thought that the suPAR scavenges the uPA and prevents its interaction with the membrane-anchored uPAR. However, since the circulating suPAR can cause FSGS by activating the podocyte β3 integrin downstream signaling pathway , there is an alternative hypothesis in which the uPA may also work as a scavenger for the suPAR in FSGS. The present study was designed to examine the role of the uPA in the pathogenesis of FSGS and further elucidate its relationship with suPAR levels.
Approval for the human subject study was granted (TSGHIRB: 094-05-0031) by the institutional review board of the Tri-service General Hospital (Taipei, Taiwan). Written consent was taken from all participants to collect and store the samples and to use medical outcome data for the purpose of the study. All participants were over 20 years old and capable of providing informed consent. Subjects seen in the Tri-service General Hospital Renal Clinic were included based on the results of a percutaneous renal biopsy with a diagnosis of FSGS and of minimal-change disease (MCD). Eighteen FSGS and 22 MCD patients were enrolled in this study. Urine and blood samples were obtained at the time of the renal biopsy. Samples were stored at − 80 °C before being analyzed.
FSGS mice model
Healthy female Balb/c inbred mice (WT) 7 weeks of ages were obtained from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan). The uPA−/− Balb/c mice (C.129S2-Plautm1Mlg/J) were originally purchased from Jackson Laboratory (Bar Harbor, Maine, USA), and bred in the animal center of National Defense Medical Center. After arrival, the animals were randomly allocated in groups of 6 in macrolon II cages. Animals were kept in a controlled specific pathogen-free environment, fed standard rodent chow ad libitum, under a 12 h day/ 12 h night rhythm. The animals were allowed to acclimatize for 1 week before starting the experimental protocol and were monitored daily for general health. Age (8 weeks) and body weight (~20 g) matched WT and uPA−/− mice were intravenously treated with Adriamycin at a dose of 10 mg/kg. At weekly intervals (W0 ~ 4), indicated numbers of WT and uPA−/− mice were euthanized (W0, n = 10; W1, n = 27; W2, n = 18; W3, n = 24; W4, n = 11). Blood samples were collected into a 1.5-ml microtube containing heparin through the retro-orbital venous plexus, and were then centrifuged (at 2500 rpm for 15 min), and the supernatant containing the plasma was withdrawn and stored at − 70 °C until for the following study. Spot urine samples were collected at indicated time point. The kidney tissues were obtained at the time of euthanization.
The animal experiments were conducted according to all applicable provisions of the Taiwan Animal Protection Act of 1998. This study was approved by the Animal Experimentation Ethical Committee of the National Defense Medical Center under permit number IACUC-13-017.
Enzyme-linked immunosorbent assay (ELISA)
Human serum levels of the suPAR were determined using a Human uPAR Quantikine ELISA Kit (DUP00, R&D, Minneapolis, MN) according to the manufacturer’s protocol. Briefly, a capture antibody was pre-coated onto microplate wells and incubated overnight at room temperature (RT). Standards and samples were introduced to the wells and incubated for 2 h at RT. After washing, a biotinylated detection antibody was added to each well and incubated for 2 h at RT, followed by the addition of 100 μL streptavidin horseradish peroxidase (HRP) and incubation for 20 min at RT. A chromogen TMB substrate solution was added to the wells and incubated for 30 min at RT. Fifty microliters of stop solution was added to each well and read at 450 nm within 30 min. The method for the mouse plasma suPAR was performed according to the Mouse uPAR DuoSet (DY531, R&D). Ten individual samples at indicated time points were randomly selected for testing.
Protein concentration in the human serum/mouse plasma samples was determined by the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL). Equal amounts (30 μg) of protein from each samples were separated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). The gel was equilibrated in transfer buffer at RT, and the protein was transferred onto polyvinylidene difluoride membranes (Millipore Immobilon-P, Sigma, St. Louis, MO) for 2.5 h at 4 °C in transfer buffer. The membranes were then blocked with 2 % bovine serum albumin (BSA) of TBST at 4 °C overnight. The next day, membranes were washed with TBST, and blots were individually incubated with antibodies against the human uPAR (MAB807, R&D) or mouse uPAR (MAB531, R&D) overnight at 4 °C, followed by incubation with a goat anti-rabbit antibodyfor 30 min at RT. Bindings were visualized with the Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences, Boston, MA) and exposed to Kodak film (Rochester, NY). Five individual samples at indicated time points were randomly selected for testing.
Evaluation of renal histopathology
Formalin-fixed and paraffin-embedded kidney tissues were cut and stained with periodic acid-Schiff (PAS) stain and colloidal iron for the general histological examination as previously described . Furthermore, to evaluate the severity of glomerular injury, glomeruli were examined using an Aperio digital microscope and quantified with the Scanscope digital program . The developed tissues were counterstained with hematoxylin. Sections were then observed with an optical photomicroscope. Negative controls were performed by omitting the primary antibodies.
Measurement of the helper T-cell 1 (Th1)/Th2 immune response
Mouse plasma concentrations of immunoglobulin G1 (IgG1), IgG2a, and IgG3 were measured using an ELISA as previously described . IgG1, IgG2a, and IgG3 mouse reference sera (mouse IgG1, IgG2a, and IgG3 quantitation kits; Enzo Life Sciences, Farmingdale, NY) were used to construct a standard curve according to the manufacturer’s instructions. Ten individual samples at indicated time points were randomly selected for testing.
Assay of cathepsin G and elastase activity
Elastase activity was detected as previously described , 50 μl blood plasma was incubated at 37 °C for 24 h with 50 μl of 1 mM elastase substrate (M4765, N-methoxy-succinyl-alanyl-alanyl-prolyl-valyl-p-nitroanilide, Sigma). The absorbance was measured on a microplate reader at 410 nm. The activity of cathepsin G was evaluated by a Cathepsin G Activity Assay Kit (ab126780, Abcam, Cambridge, MA), and all procedures were performed according to the manufacturer’s instructions. Six individual samples at indicated time points were randomly selected for testing.
The statistical analysis of differences between groups was performed by a t-test. Significance was defined as p < 0.05. Pearson correlation coefficients were calculated for normally distributed variables; otherwise Spearman correlation coefficients were calculated. Data are expressed as the mean ± standard error (SE).
FSGS patients showed higher suPAR and lower uPA levels
Biochemical and serologic features of clinical subjects
36.00 ± 4.25
3 F/19 M
2.03 ± 0.18
0.44 ± 0.15
1.13 ± 0.26
7.7 ± 0.03
56.83 ± 8.29
4 F/14 M
3.67 ± 0.17*
0.1 ± 0.02*
3.42 ± 1.41*
8.92 ± 4.12
Deficiency of the uPA accelerated the progression of FSGS in a mice model
Both the intact and cleaved forms of the suPAR were higher in FSGS, and the uPA, elastase, and cathepsin G were not involved in the cleavage process
The meaning of circulating suPAR levels in FSGS is still under debate. In two different ethnic cohorts of primary FSGS, serum suPAR levels were elevated in 84.3 and 55.3 % of FSGS patients, while only in about 6 % of control subjects. Treatment with mycophenolate mofetil and reduction of proteinuria were both associated with a reduction in suPAR, and gave higher odds for complete remission in a clinical trial study . Furthermore, evidence has been reported that NPHS2 mutations were detected in 45 % ~ 55 % of families and 8 % ~ 20 % of patients with sporadic nephrotic syndrome . FSGS patients with an NPHS2 mutation also presented higher suPAR levels than those without a mutation . However, recent studies suggested that eGFR is a potent determinant of suPAR levels [4, 30] and that an absolute, eGFR-independent, suPAR concentration cutoff (3.0 ng/ml) could not successfully be determined for FSGS patients . In addition, Sinha et al. reported that suPAR levels could not identify FSGS among other causes of nephrotic syndrome in children . In another study, suPAR levels were increased, but researchers were unable to distinguish primary from secondary FSGS . In the current study, FSGS patients had higher suPAR levels (3.67 ± 0.17 ng/ml) compared to MCD patients (2.13 ± 0.18 ng/ml) and serum suPAR levels showed a moderate correlation to serum Cr levels in FSGS patients. Furthermore, suPAR levels were significantly higher at W1 after Adriamycin treatment and stayed elevated throughout the study. The uPA-deficient mice model showed higher suPAR levels and faster disease progression than WT mice. These data indicate that suPAR levels can be used to evaluate the disease in both clinical subjects and an animal model of FSGS.
It is of note that, in addition to FSGS, increased concentration of suPAR has been observed in different glomerular diseases. In a recent study, we also found serum suPAR was elevated in most kidney diseases, such as diabetic nephropathy , but not MCD. Zhao et al. also reported plasma suPAR levels of patients with IgA nephropathy (IgAN) were significantly lower than those in patients with primary FSGS, and higher than those with MN, MCD and healthy controls. In IgAN patients, plasma suPAR levels were positively associated with proteinuria and negatively associated with eGFR . Although serum suPAR levels had some diagnostic value in FSGS, a more precise determinant cut-off value and suPAR combinations with other biomarkers are still needed.
Although use of suPAR as a diagnosis tool is under debate, it is certainly a factor in the pathogenesis of FSGS. The current methodology of determining suPAR levels might not be able to reliably distinguish FSGS from other proteinuric glomerular diseases . It has been suggested that variants of the suPAR may also have diagnostic and prognostic values , which may be another indicator for an FSGS diagnosis. Herein, we performed a WB analysis to differentiate the suPAR variants in both animal models and clinical subjects. As shown in Fig. 5, the cleaved form increased in the FSGS animal model after induction. Both the intact and cleaved forms increased in clinical subjects, but this process was not mediated by uPA, elastase, or cathepsin G. Wei et al., reported circulating suPAR regulated kidney permeability via β3 integrin down-stream signaling in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1 . However, which fractions of suPAR mediated the activation of β3 integrin remains unclear. In a recently study, Alfano et al., provided in vitro evidence that full-length suPAR but not cleaved suPAR variant has the capability to induce nephrin down-regulation in human podocytes . The detailed mechanisms and functions of increased cleavage in suPAR variants in FSGS still need further investigation. Although it is still too early to draw conclusions about suPAR variants in an FSGS diagnosis, we hope to have additional information after further studies. In addition to serum suPAR levels for an FSGS diagnosis, it was reported that the urinary suPAR is elevated and pathogenic in patients with primary FSGS  and may be used to identify cases of recurrent FSGS in kidney transplant candidates .
Expansion of the extracellular matrix (ECM) might not only result from increased matrix protein synthesis by fibroblasts but also from decreased degradation by proteases such as metalloproteinases and serine proteases. Actually, uPA is considered to be a logical source of endogenous renal antifibrotic activity through enhancing the process of protein degradation . In addition, uPA has been reported to have the ability to promote tissue repair through activation of growth factors, such as hepatocyte growth factor (HGF) [40, 41]. Stimulation of podocytes with HGF in vitro resulted in antiapoptotic phosphorylation of AKT and extracellular signal-regulated kinase and induction of the X-linked inhibitor of apoptosis protein. In the same study, diminution of the HGF downstream signaling pathway in podocytes contributes to cell loss and FSGS in transplant glomerulopathy . However, evidence from uPA and uPAR deficient animals has shown other molecules, such as vitronectin and high molecular weight kininogen, are alternate uPAR ligands, and receptors in addition to uPAR may also bind directly to uPA and activate cell signaling pathways . In a renal interstitial fibrosis obstructive nephropathy model (UUO) , uPAR deficiency suppressed renal macrophage recruitment but exacerbated the fibrogenic response, which may partly have occurred through the delayed clearance of angiogenic/profibrotic molecules and decreased receptor-associated uPA activity. In addition, the number of apoptotic tubulointerstitial cells was also significantly increased in uPAR deficient mice . In contrast, Yamaguchi I et al., found uPA deficiency had no role in the inhibition of interstitial fibrosis in the UUO model, and suggested an organ-specific difference in basic fibrogenic pathways . Treatment with recombinant suPAR to uPAR-knockout mice with 20 μg and greater led to albuminuria within 24 h. In addition, sustained overexpression of suPAR in the blood of WT mice leads to an FSGS-like glomerulopathy . Here, we used an Adriamycin-induced FSGS model in uPA- knockout mice to elucidate the role of uPA in FSGS. In the mice model of our current study, uPA deficient accelerated Adriamycin-induced FSGS in the early stage, but did not increase the severity in the late stage (Fig. 3). This evidence suggests uPA may play only a partial role in ameliorating ECM expansion in the initial stage of FSGS.
It has been claimed that the pathogenesis of FSGS is mainly mediated by the podocyte damage and loss. This pathological process includes dysregulated slit diaphragm, cytoskeleton, glomerular basement membrane, and affected negative surface charge of the podocyte. An injured podocyte will trigger cell apoptosis and detachment from glomerular basement membrane, loss of glomerular structural integrity and result in sclerosis and scarring of the glomerulus . In the current study, we observed that the increase of glomerular apoptotic cells and lower glomerular polyanions in uPA- deficient mice might imply an anti-apoptotic role of uPA in the pathogenesis of FSGS (Fig. 3). The underlying mechanisms may be mediated through the activation of caspase-mediated apoptosis and inhibit the PI3K/AKT pathway . In addition, uPA has been suggested as a major determinant of the basal level of activated ERK/MAP kinase, and may prevent cell apoptosis . However, it has been reported that uPA increases survival or pro-apoptotic signals in human mesangial cells depending on the apoptotic stimulus . The detailed mechanisms of uPA anti-apoptotic activity still need further investigation.
The immunological mechanisms involved in the pathogenesis of FSGS are unclear, but evidence suggests an association between Th2-polarization and disease development . For example, Yap et al. reported a correlation between childhood idiopathic nephrotic syndrome and increased IL-13 mRNA expression. In Buffalo/Mna spontaneously developed FSGS rat model, a predominantly Th2 mRNA profile and the down-regulation of Th1 cytokine mRNA was also observed . It is known Th1 and Th2 cells can provide B-cell help, and their signature cytokines IFN-γ and IL-4 induce class switch recombination to IgG2a and IgG3 or IgG1 and IgE, respectively . In our study, uPA-deficient animals didn’t switch to IgG2a and IgG3, but the progression of FSGS was still accelerated. This indicates the role of Th2 polarization maybe less important than a uPA deficiency in the mice model of FSGS induced by Adriamycin. At present, we are the first group to present the idea and possible hypothesis of the role of Th2 polarization in the development of FSGS which may be only applicable in certain models or conditions and not a general effect.
In summary, we found that the increase in suPAR and decrease in uPA levels both occurred in FSGS clinical subjects. A gradual increase in suPAR levels was also present in a mouse model of Adriamycin-induced FSGS. In addition, disruption of uPA accelerated the onset of FSGS and exacerbated its severity in proteinuria and cell apoptosis. Dysregulation of the Th1/Th2 balance may also be involved in uPA-regulated disease progression. In addition, the suPAR in FSGS animals was manifested in the cleaved form, while it was predominantly in the intact form in control animals, and the cleavage process was not mediated by the uPA, elastase, or cathepsin G through an enzymatic process. These data suggest the levels of serum uPA may be an indicator for the progression of FSGS in clinical subjects and animal models.
We thank all subjects who participated in the study. This work was supported by grants from the National Defense Medical Center, the Tri-Service General Hospital (TSGH-C103-007-S02), and the Ministry of Science and Technology of Taiwan (MOST 102-2314-B-016-012-), Taiwan. This work was also partly supported by a grant from Taipei Medical University (TMU100-AE3-Y06). The authors thank Ms. Hsin-Yi Tsai for her technical support.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- McCarthy ET, Swan SK, Ellis E, Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334:878–83.View ArticlePubMedGoogle Scholar
- Fornoni A, Goes N, Sageshima J, Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong C, Friedman AL, Gassman JJ, Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23:2051–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Bammens B, Poesen R, Claes K, Meijers B, Maas RJ, Sprangers B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014;85:636–40.View ArticlePubMedGoogle Scholar
- Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol. 2013;28:1041–8.View ArticlePubMedGoogle Scholar
- Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987;104:801–4.View ArticlePubMedGoogle Scholar
- Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Gerard CJ, Rosenberg S, Chapman HA, Waltz DA, Fujita RM, Yang X, et al. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol. 2000;22:316–22.View ArticlePubMedGoogle Scholar
- Bender JR, Blasi F, Pardi R, Bianchi E, Ferrero E, Fazioli F, et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest. 1996;98:1133–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Dinh DH, Gujrati M, Rao JS, Raghu H, Lakka SS, Gondi CS, et al. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One. 2010;5:e12458.View ArticlePubMedPubMed CentralGoogle Scholar
- Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 1994;349:163–8.View ArticlePubMedGoogle Scholar
- Jensen AL, Blasi F, Danø K, Ploug M, Ronne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991;266:1926–33.PubMedGoogle Scholar
- Gilquin B, Stura EA, Ménez A, Llinas P, Le Du MH, Gardsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005;24:1655–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Furie BC, Cines DB, Huang M, Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006;311:656–9.View ArticlePubMedGoogle Scholar
- Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–43.View ArticlePubMedGoogle Scholar
- Hoyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem. 2007;44:65–102.View ArticlePubMedGoogle Scholar
- Weidle U, Danø K, Behrendt N, Hoyer-Hansen G, Pessara U, Holm A, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J. 2001;358:673–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Lund LR, Ellis V, Danø K, Hoyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267:18224–9.PubMedGoogle Scholar
- Elonen E, Alitalo R, Vaheri A, Mustjoki S, Sidenius N, Sier CF, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res. 2000;60:7126–32.PubMedGoogle Scholar
- Dybkjaer E, Danø K, Brünner N, Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem. 1997;43:1868–76.PubMedGoogle Scholar
- Slot O, Brunner N, Locht H, et al. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999;58:488–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci. 2008;13:6752–62.View ArticlePubMedGoogle Scholar
- Chen A, Sytwu HK, Lin YF, Wu CC, Chen JS, Lin SH, et al. Experimental model of membranous nephropathy in mice: sequence of histological and biochemical events. Lab Anim. 2008;42:350–9.View ArticlePubMedGoogle Scholar
- Ljubanović D, Holers VM, Thurman JM, Strassheim D, Renner B, Panzer S, et al. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol. 2013;24:393–406.View ArticlePubMedPubMed CentralGoogle Scholar
- Donati S, Orefici G, Nisini R, Teloni R, von Hunolstein C, Mariotti S, et al. Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs. Indian J Med Res. 2004;119:126–30.PubMedGoogle Scholar
- Altshuler AE, Penn AH, Yang JA, Kim GR, Schmid-Schönbein GW. Protease activity increases in plasma, peritoneal fluid, and vital organs after hemorrhagic shock in rats. PLoS One. 2012;7:e32672.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng CW, Chang WL, Chang LC, Wu CC, Lin YF, Chen JS. Ferulic Acid, an Angelica sinensis-Derived Polyphenol, Slows the Progression of Membranous Nephropathy in a Mouse Model. Evid Based Complement Alternat Med 2012; 2012: 161235 doi:10.1155/2012/161235.
- Namane A, Chignard M, Pidard D, Beaufort N, Leduc D, Rousselle JC, et al. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004;172:540–9.View ArticlePubMedGoogle Scholar
- Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res. 2005;57:54R–61R.View ArticlePubMedGoogle Scholar
- Bagga A, Hari P, Pandey RM, Sinha A, Bajpai J, Saini S, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014;85:649–58.View ArticlePubMedGoogle Scholar
- Chu R, Chen Y, Zhao MH, Huang J, Liu G, Zhang YM, et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int. 2013;84:366–72.View ArticlePubMedGoogle Scholar
- Chen JS, Chu NF, Pei D, Wu CZ, Chang LC, Lin YF, et al. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. Clin Biochem. 2015;48(18):1324–9.View ArticlePubMedGoogle Scholar
- Zhang H, Zhao M, Liu G, Zhao Y, Liu L, Huang J, et al. Plasma soluble urokinase receptor level is correlated with podocytes damage in patients with IgA nephropathy. PLoS One. 2015;10:e0132869.View ArticlePubMedPubMed CentralGoogle Scholar
- Schlondorff D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int. 2014;85:499–501.View ArticlePubMedGoogle Scholar
- Carmeliet P, Mundel P, Reiser J, Wei C, Moller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14:55–63.View ArticlePubMedGoogle Scholar
- Mikulak J, Mavilio D, Saleem MA, Alfano M, Cinque P, Giusti G, et al. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Sci Rep. 2015;5:13647.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao MH, Chu R, Liu XJ, Huang J, Liu G, Zhang YM, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014;12:81.View ArticlePubMedPubMed CentralGoogle Scholar
- Stegall MD, Cosio FG, Amer H, Franco Palacios CR, Lieske JC, Wadei HM, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013;96:394–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Collins SJ, Okamura DM, Eddy AA, Yamaguchi I, Lopez-Guisa JM, Cai X, et al. Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol. 2007;293:F12–19.View ArticlePubMedGoogle Scholar
- Novak ML, Simon RH, Koh TJ, Sisson TH, Nguyen MH, Yu B, et al. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood. 2009;114:5052–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsubouchi H, Blasi F, Comoglio PM, Naldini L, Tamagnone L, Vigna E, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992;11(Naldini L, Tamagnone L, Vigna E):4825–33.PubMedPubMed CentralGoogle Scholar
- Kreipe HH, Bröcker V, Becker JU, Agustian PA, Schiffer M, Gwinner W, et al. Diminished met signaling in podocytes contributes to the development of podocytopenia in transplant glomerulopathy. Am J Pathol. 2011;178:2007–19.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang G, Eddy AA. Urokinase and its receptors in chronic kidney disease. Front Biosci. 2008;13:5462–78.View ArticlePubMedPubMed CentralGoogle Scholar
- Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75:1145–52.View ArticlePubMedGoogle Scholar
- Lopez-Guisa JM, Carmeliet P, Eddy AA, Zhang G, Kim H, Cai X, et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol. 2003;14:1234–53.View ArticlePubMedGoogle Scholar
- Reidy K, Kaskel FJ. Pathophysiology of focal segmental glomerulosclerosis. Pediatr Nephrol. 2007;22:350–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol. 2007;31:19–27.PubMedPubMed CentralGoogle Scholar
- Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci. 2001;114:3387–96.PubMedGoogle Scholar
- Shushakova N, Haller H, Dumler I, Tkachuk N, Kiyan J, Tkachuk S, et al. Urokinase induces survival or pro-apoptotic signals in human mesangial cells depending on the apoptotic stimulus. Biochem J. 2008;415:265–73.View ArticlePubMedGoogle Scholar
- Savage PB, Câmara NO, Keller AC, Pereira RL, Reis VO, Semedo P, et al. Invariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosis. PLoS One. 2012;7:e32454.View ArticlePubMedPubMed CentralGoogle Scholar
- Sim SK, Seah CC, Jordan SC, Yap HK, Cheung W, Murugasu B, et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol. 1999;10:529–37.PubMedGoogle Scholar
- Taylor DR, MacLennan IC, Acha-Orbea H, Toellner KM, Luther SA, Sze DM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med. 1998;187:1193–204.View ArticlePubMedPubMed CentralGoogle Scholar